 Brett Stevens
Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 26 | 2025 | 686 | 3.780 |
Why?
| | Neoplastic Stem Cells | 15 | 2025 | 409 | 1.800 |
Why?
| | Myelodysplastic Syndromes | 4 | 2020 | 148 | 1.650 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 15 | 2025 | 280 | 1.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 13 | 2025 | 1965 | 1.340 |
Why?
| | Sulfonamides | 15 | 2025 | 581 | 1.120 |
Why?
| | Azacitidine | 9 | 2025 | 157 | 1.110 |
Why?
| | Proto-Oncogene Proteins c-cbl | 3 | 2014 | 13 | 0.950 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2025 | 881 | 0.910 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 17 | 0.740 |
Why?
| | Flow Cytometry | 3 | 2020 | 1156 | 0.680 |
Why?
| | Multiple Myeloma | 4 | 2025 | 309 | 0.580 |
Why?
| | Hematopoietic Stem Cells | 2 | 2021 | 419 | 0.570 |
Why?
| | Reactive Oxygen Species | 2 | 2020 | 602 | 0.560 |
Why?
| | Salvage Therapy | 1 | 2019 | 165 | 0.540 |
Why?
| | Proto-Oncogene Proteins c-fyn | 2 | 2014 | 10 | 0.540 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2018 | 337 | 0.540 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 5 | 0.470 |
Why?
| | Mice, Inbred NOD | 7 | 2020 | 613 | 0.460 |
Why?
| | Leukocytosis | 1 | 2015 | 32 | 0.460 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 342 | 0.450 |
Why?
| | Clonal Evolution | 1 | 2015 | 47 | 0.440 |
Why?
| | Mice, SCID | 5 | 2020 | 369 | 0.440 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2014 | 27 | 0.420 |
Why?
| | Oxidative Phosphorylation | 6 | 2024 | 209 | 0.410 |
Why?
| | Computational Biology | 1 | 2019 | 687 | 0.410 |
Why?
| | Interferon Regulatory Factors | 3 | 2024 | 44 | 0.400 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 1150 | 0.390 |
Why?
| | Proto-Oncogene Proteins c-myc | 3 | 2024 | 167 | 0.380 |
Why?
| | Cell Proliferation | 4 | 2021 | 2499 | 0.380 |
Why?
| | Leukemia | 3 | 2020 | 246 | 0.380 |
Why?
| | Mutation | 3 | 2024 | 4093 | 0.380 |
Why?
| | Carrier Proteins | 1 | 2015 | 733 | 0.340 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2025 | 127 | 0.330 |
Why?
| | Nuclear Proteins | 1 | 2015 | 743 | 0.320 |
Why?
| | Glioblastoma | 1 | 2014 | 353 | 0.320 |
Why?
| | Neutrophils | 1 | 2015 | 1124 | 0.300 |
Why?
| | Neoplasm, Residual | 3 | 2024 | 143 | 0.280 |
Why?
| | Cell Self Renewal | 2 | 2019 | 52 | 0.280 |
Why?
| | Mice | 18 | 2025 | 18338 | 0.270 |
Why?
| | Humans | 43 | 2025 | 145491 | 0.270 |
Why?
| | Stem Cells | 3 | 2020 | 626 | 0.260 |
Why?
| | Fatty Acids | 3 | 2020 | 459 | 0.260 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1321 | 0.240 |
Why?
| | Animals | 21 | 2025 | 38141 | 0.240 |
Why?
| | Cell Line, Tumor | 8 | 2025 | 3537 | 0.230 |
Why?
| | Amino Acids | 2 | 2020 | 521 | 0.230 |
Why?
| | Protein Kinase Inhibitors | 3 | 2025 | 980 | 0.230 |
Why?
| | Ikaros Transcription Factor | 1 | 2024 | 23 | 0.210 |
Why?
| | Thalidomide | 1 | 2024 | 43 | 0.210 |
Why?
| | Ribosomes | 1 | 2025 | 196 | 0.200 |
Why?
| | Tumor Cells, Cultured | 4 | 2022 | 883 | 0.200 |
Why?
| | Finland | 1 | 2023 | 78 | 0.200 |
Why?
| | Uncertainty | 1 | 2023 | 147 | 0.180 |
Why?
| | Electron Transport Complex II | 2 | 2019 | 28 | 0.180 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.180 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 455 | 0.180 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2025 | 452 | 0.180 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 47 | 0.170 |
Why?
| | Survival Rate | 3 | 2025 | 2093 | 0.170 |
Why?
| | Aged, 80 and over | 7 | 2025 | 8326 | 0.170 |
Why?
| | Trans-Activators | 2 | 2021 | 397 | 0.170 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 1 | 2020 | 11 | 0.160 |
Why?
| | Bone Marrow Diseases | 1 | 2020 | 20 | 0.160 |
Why?
| | Lipids | 1 | 2025 | 709 | 0.160 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 48 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2020 | 56 | 0.160 |
Why?
| | RNA Splicing Factors | 1 | 2020 | 66 | 0.160 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 205 | 0.160 |
Why?
| | Lipase | 1 | 2020 | 75 | 0.160 |
Why?
| | Oxidation-Reduction | 4 | 2019 | 1080 | 0.150 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 176 | 0.150 |
Why?
| | Aged | 10 | 2025 | 26125 | 0.150 |
Why?
| | Mitochondria | 2 | 2024 | 990 | 0.150 |
Why?
| | Leukopoiesis | 1 | 2019 | 11 | 0.150 |
Why?
| | Lentivirus | 1 | 2019 | 61 | 0.150 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 16 | 0.150 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 32 | 0.150 |
Why?
| | Signal Transduction | 5 | 2022 | 5202 | 0.150 |
Why?
| | Neoplasms | 1 | 2014 | 2897 | 0.140 |
Why?
| | Cytarabine | 1 | 2019 | 66 | 0.140 |
Why?
| | Histone Deacetylases | 1 | 2020 | 207 | 0.140 |
Why?
| | Thrombocytopenia | 1 | 2020 | 203 | 0.140 |
Why?
| | Mitochondrial Proteins | 2 | 2018 | 262 | 0.140 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2019 | 105 | 0.140 |
Why?
| | Calcium | 1 | 2024 | 1190 | 0.140 |
Why?
| | Female | 18 | 2025 | 78763 | 0.140 |
Why?
| | Phosphoproteins | 1 | 2020 | 339 | 0.140 |
Why?
| | Bone Marrow | 2 | 2020 | 307 | 0.140 |
Why?
| | Male | 14 | 2025 | 72817 | 0.140 |
Why?
| | Homeostasis | 2 | 2021 | 639 | 0.140 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 271 | 0.140 |
Why?
| | Cell Survival | 3 | 2022 | 1094 | 0.140 |
Why?
| | RNA Interference | 3 | 2014 | 473 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 917 | 0.130 |
Why?
| | Cysteine | 1 | 2019 | 208 | 0.130 |
Why?
| | Cation Transport Proteins | 1 | 2019 | 118 | 0.130 |
Why?
| | Stress, Physiological | 1 | 2021 | 452 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 620 | 0.130 |
Why?
| | Arthritis, Experimental | 1 | 2019 | 141 | 0.130 |
Why?
| | Prognosis | 5 | 2025 | 4323 | 0.130 |
Why?
| | Repressor Proteins | 1 | 2020 | 430 | 0.130 |
Why?
| | Transplantation, Heterologous | 2 | 2014 | 169 | 0.120 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2018 | 191 | 0.120 |
Why?
| | Cells, Cultured | 3 | 2019 | 4127 | 0.120 |
Why?
| | Tumor Burden | 2 | 2016 | 324 | 0.120 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 441 | 0.120 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 56 | 0.120 |
Why?
| | HEK293 Cells | 2 | 2019 | 743 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 2016 | 61 | 0.120 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 100 | 0.110 |
Why?
| | Gene Expression | 1 | 2020 | 1478 | 0.110 |
Why?
| | Middle Aged | 8 | 2025 | 36176 | 0.110 |
Why?
| | Methyltransferases | 1 | 2016 | 75 | 0.110 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 72 | 0.110 |
Why?
| | Cytokines | 3 | 2020 | 2054 | 0.110 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.110 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 164 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 469 | 0.110 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 23 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 324 | 0.110 |
Why?
| | Machine Learning | 3 | 2025 | 590 | 0.110 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2014 | 51 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 409 | 0.110 |
Why?
| | Carmustine | 1 | 2014 | 52 | 0.100 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 141 | 0.100 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2014 | 72 | 0.100 |
Why?
| | Dacarbazine | 1 | 2014 | 100 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 320 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2024 | 17269 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2129 | 0.100 |
Why?
| | Spheroids, Cellular | 1 | 2014 | 74 | 0.100 |
Why?
| | cdc42 GTP-Binding Protein | 1 | 2013 | 21 | 0.100 |
Why?
| | Glucose | 1 | 2018 | 1039 | 0.100 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 68 | 0.100 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2207 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5426 | 0.090 |
Why?
| | Tamoxifen | 1 | 2013 | 191 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1081 | 0.090 |
Why?
| | Adaptation, Physiological | 1 | 2016 | 570 | 0.090 |
Why?
| | Inflammation | 2 | 2021 | 2883 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1895 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2016 | 644 | 0.090 |
Why?
| | Blotting, Western | 1 | 2014 | 1162 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2018 | 1164 | 0.090 |
Why?
| | Blast Crisis | 2 | 2025 | 34 | 0.080 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5989 | 0.080 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 1177 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2018 | 1244 | 0.080 |
Why?
| | Adult | 6 | 2025 | 40707 | 0.080 |
Why?
| | Succinate Dehydrogenase | 2 | 2019 | 66 | 0.070 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2008 | 11 | 0.070 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 72 | 0.070 |
Why?
| | Young Adult | 3 | 2021 | 14192 | 0.070 |
Why?
| | Protein Binding | 1 | 2014 | 2250 | 0.070 |
Why?
| | Fresh Water | 1 | 2008 | 56 | 0.070 |
Why?
| | Energy Metabolism | 3 | 2019 | 932 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 238 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2020 | 4559 | 0.060 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 296 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2016 | 3125 | 0.050 |
Why?
| | Biodiversity | 1 | 2008 | 429 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 89 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2024 | 11831 | 0.050 |
Why?
| | Disease Progression | 2 | 2023 | 2862 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2014 | 632 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 87 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1049 | 0.040 |
Why?
| | Bacteria | 1 | 2008 | 897 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2020 | 34 | 0.040 |
Why?
| | Spliceosomes | 1 | 2020 | 54 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 38 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2373 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 191 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 172 | 0.040 |
Why?
| | Niacinamide | 1 | 2020 | 87 | 0.040 |
Why?
| | Drug Synergism | 1 | 2020 | 353 | 0.040 |
Why?
| | Adolescent | 1 | 2019 | 22485 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 33 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 11 | 0.040 |
Why?
| | Protein Transport | 1 | 2020 | 438 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 23 | 0.040 |
Why?
| | RNA Splicing | 1 | 2020 | 286 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2018 | 2189 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 309 | 0.040 |
Why?
| | Apoptosis | 2 | 2018 | 2411 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1439 | 0.030 |
Why?
| | Cell Cycle | 1 | 2021 | 595 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 207 | 0.030 |
Why?
| | Cohort Studies | 2 | 2020 | 5992 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 505 | 0.030 |
Why?
| | Biological Transport | 1 | 2018 | 422 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 929 | 0.030 |
Why?
| | Glutathione | 1 | 2019 | 366 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 264 | 0.030 |
Why?
| | Glycolysis | 1 | 2018 | 342 | 0.030 |
Why?
| | NADP | 1 | 2016 | 53 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 480 | 0.030 |
Why?
| | CD36 Antigens | 1 | 2016 | 32 | 0.030 |
Why?
| | Gonads | 1 | 2016 | 22 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2019 | 503 | 0.030 |
Why?
| | Cytoprotection | 1 | 2016 | 56 | 0.030 |
Why?
| | Sesquiterpenes | 1 | 2016 | 52 | 0.030 |
Why?
| | Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2016 | 11 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 49 | 0.030 |
Why?
| | Lipolysis | 1 | 2016 | 44 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 737 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2016 | 246 | 0.030 |
Why?
| | Risk Assessment | 1 | 2025 | 3759 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2016 | 320 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 846 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 387 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 529 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 74 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2014 | 77 | 0.030 |
Why?
| | Sirolimus | 1 | 2016 | 280 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 199 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 848 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2021 | 2045 | 0.020 |
Why?
| | Recurrence | 1 | 2016 | 1142 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1511 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2016 | 525 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2355 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 151 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 431 | 0.020 |
Why?
| | New York | 1 | 2008 | 127 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4283 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2506 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2008 | 196 | 0.020 |
Why?
| | Geography | 1 | 2008 | 204 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2008 | 563 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2008 | 565 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2008 | 831 | 0.010 |
Why?
| | Prospective Studies | 1 | 2016 | 8039 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2910 | 0.010 |
Why?
| | Phylogeny | 1 | 2008 | 1028 | 0.010 |
Why?
| | Child | 1 | 2020 | 22680 | 0.010 |
Why?
|
|
Stevens's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|